EcoR1 Capital, LLC - Q1 2022 holdings

$3.2 Billion is the total value of EcoR1 Capital, LLC's 87 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was - .

 Value Shares↓ Weighting
SRPT NewSAREPTA THERAPEUTICS INC$161,680,0002,069,634
+100.0%
5.06%
ZLAB NewZAI LAB LTDadr$97,777,0002,223,212
+100.0%
3.06%
RETA NewREATA PHARMACEUTICALS INCcl a$64,721,0001,975,611
+100.0%
2.02%
CERE NewCEREVEL THERAPEUTICS HLDNG I$57,636,0001,646,260
+100.0%
1.80%
MRTX NewMIRATI THERAPEUTICS INC$41,161,000500,622
+100.0%
1.29%
ARGX NewARGENX SEsponsored adr$39,414,000125,000
+100.0%
1.23%
RVMD NewREVOLUTION MEDICINES INC$32,502,0001,274,097
+100.0%
1.02%
BCYC NewBICYCLE THERAPEUTICS PLCsponsored ads$24,022,000547,453
+100.0%
0.75%
EXEL NewEXELIXIS INC$21,567,000951,333
+100.0%
0.68%
GERN NewGERON CORP$19,429,00014,285,714
+100.0%
0.61%
SWTX NewSPRINGWORKS THERAPEUTICS INC$18,393,000325,881
+100.0%
0.58%
ARQT NewARCUTIS BIOTHERAPEUTICS INC$17,247,000895,503
+100.0%
0.54%
SURF NewSURFACE ONCOLOGY INC$13,680,0004,653,000
+100.0%
0.43%
HOOK NewHOOKIPA PHARMA INC$11,400,0005,000,000
+100.0%
0.36%
KDNY NewCHINOOK THERAPEUTICS INC$11,288,000690,000
+100.0%
0.35%
NGM NewNGM BIOPHARMACEUTICALS INC$8,252,000541,108
+100.0%
0.26%
IGMS NewIGM BIOSCIENCES INC$7,981,000298,597
+100.0%
0.25%
ZNTL NewZENTALIS PHARMACEUTICALS INC$5,317,000115,236
+100.0%
0.17%
GRCL NewGRACELL BIOTECHNOLOGIES INCsponsored ads$3,634,0001,559,710
+100.0%
0.11%
MRSN NewMERSANA THERAPEUTICS INC$1,303,000326,578
+100.0%
0.04%
BCEL NewATRECA INC$1,137,000358,780
+100.0%
0.04%
EUCRW NewEUCRATES BIOMEDICAL ACQU CORcall$656,00066,666
+100.0%
0.02%
RDUS NewRADIUS HEALTH INC$309,00035,000
+100.0%
0.01%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2022-05-16
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
KURA ONCOLOGY ORD32Q3 202310.5%
XENCOR ORD25Q3 202312.6%
ASSEMBLY BIOSCIENCES ORD23Q3 202019.0%
FIBROGEN ORD22Q1 202012.4%
PROTHENA ORD20Q3 202328.0%
IRONWOOD PHARMA CL A ORD20Q1 202013.9%
GALAPAGOS NV SPON ADR19Q3 202312.0%
MORPHIC HOLDING ORD18Q3 20238.5%
ARCUS BIOSCIENCES ORD17Q1 20227.1%
ANAPTYSBIO INC16Q3 20238.3%

View EcoR1 Capital, LLC's complete holdings history.

Latest significant ownerships (13-D/G)
EcoR1 Capital, LLC Q1 2022 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Mersana Therapeutics, Inc.July 27, 202319,364,68816.9%
TScan Therapeutics, Inc.June 05, 20235,000,00011.7%
2seventy bio, Inc.February 14, 20231,143,4943.0%
Avidity Biosciences, Inc.Sold outFebruary 14, 202300.0%
Surface Oncology, Inc.February 13, 20233,924,7136.5%
Akouos, Inc.Sold outFebruary 10, 202300.0%
Alector, Inc.February 10, 20234,056,5484.9%
Arcus Biosciences, Inc.Sold outFebruary 10, 202300.0%
Gritstone bio, Inc.Sold outFebruary 10, 202300.0%
Ovid Therapeutics Inc.February 10, 20236,117,4008.7%

View EcoR1 Capital, LLC's complete significant-ownership history.

Latest filings
TypeFiled
SC 13G2024-05-03
SC 13G/A2024-04-08
32024-03-26
SC 13G/A2024-03-26
SC 13G2024-03-11
SC 13D2024-02-22
SC 13G2024-02-16
13F-HR2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14

View EcoR1 Capital, LLC's complete filings history.

Compare quarters

Export EcoR1 Capital, LLC's holdings